Products
Mifamurtide is commercially available as a powder for a concentrate for the preparation of an infusion dispersion (Mepact). It was approved in the EU in 2009 and in many countries in 2010. It was originally developed in the early 1980s at Ciba-Geigy.
Structure and properties
Mifamurtide (L-MTP-PE) is a fully synthetic derivative of muramyl dipeptide (MDP), a cell wall component of mycobacteria. Mifamurtide is less pyrogenic and longer acting than the natural parent compound MDP.
Effects
Like MDP, mifamurtide (ATC L03AX15) has immunostimulatory properties. It activates immune cells (macrophages, monocytes) and promotes the release of mediators, which include cytokines, for example. This leads to the indirect antitumor effect. It is a cancer immunotherapy. The liposomal preparation is taken up by macrophages after infusion.
Indications
Along with postoperative combination chemotherapy for the treatment of nonmetastatic, resectable highly malignant osteosarcoma. Following macroscopically complete tumor resection.
Dosage
According to the SmPC. The drug is administered as an intravenous infusion.
Contraindications
- Hypersensitivity
- Combination with ciclosporin and calcineurin inhibitors.
- Combination with high-dose NSAIDs
Full precautions can be found in the drug label.
Adverse effects
The most common possible adverse effects include chills, fever, fatigue, nausea, rapid pulse (tachycardia), and headache.
